SANTA ANA, Calif., Oct. 02, 2023 (GLOBE NEWSWIRE) — NKGen Biotech, Inc. (“NKGen” or the “Company”), a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic, and CAR-NK natural killer (“NK”) cell therapies, today announced that it has closed its previously announced business combination with Graf…Read More
NKGen Biotech Inc Announces Closing of Business Combination
